4 registrations that name hesperidin as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 4 registrations
Status
Phase
1US sites across 1 state
1
2 to 4
5 to 19
20 or more
All 4 registrations
RecruitingNCT06672952
Dose-Response Impact of Glucosyl-Hesperidin (CitraPeak) on Exercise Performance, Blood Flow, Stress, Cognition, and Other Perceptual Indicators
No phase
Lindenwood University
About 60 people
Started Apr 15, 2025
In plain words A study of hesperidin in people 18 to 50, run by Lindenwood University. It plans to enroll about 60 people at 1 US site.
Body mass index values will range from >25.0 < 30.0 kg/m2
The average body mass index for entire study cohort will be less than 27.0 kg/m2. As such an ongoing calculation of the recruited cohort's mean body mass index will be maintained and people will only be randomized into the study if the…
Free-living and independent
4 more inclusion criteria and the exclusion criteria are on the listing.
The purpose of this study is to evaluate the dose-dependent effects of glucosyl-hesperidin (CITRAPEAK) supplementation on exercise performance, recovery indicators, blood flow, cognitive function, mood, sleep, and fuel utilization in recreationally active adults.
Where, as registered
1 US site in 1 state.
RecruitingNCT06584799
Venoactive Drug Treatment of Pelvic Venous Disorders
Phase 3
Pirogov Russian National Research Medical University
About 150 people
Starts Dec 2024 (estimated)
In plain words A Phase 3 study of hesperidin in female participants 18 to 45, run by Pirogov Russian National Research Medical University. It plans to enroll about 150 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 to 45. Conditions: Pelvic Venous Disorders.
Age from 18 to 45 years;
The presence of PeVD symptoms (CPP, dyspareunia, discomfort in the hypogastrium, dysuria, vulvar varicose veins);
The presence of pelvic varicose veins with reflux in them, according to DUS;
Pelvic venous reflux (PVR) lasting for greater than 1 s, according to DUS;
2 more inclusion criteria and the exclusion criteria are on the listing.
Venoactive drug (VAD) therapy is one of the most effective methods of treating chronic venous diseases (CVD). Numerous studies have proven its high efficacy in relieving symptoms of CVD, such as leg pain and swelling, leg heaviness and fatigue. Pelvic venous disorders (PeVDs) represent a group of pathological conditions including varicose veins of the pelvis and vulva, and compression stenoses of the left renal and common iliac veins. The full summary is on the listing.
Where, as registered
No US site; Russia (1).
RecruitingNCT07750223
Cognitive Effects of Hesperidin in Overweight/Obese Older Adults
No phase
Min Hou
About 105 people
Started Feb 1, 2026
In plain words A study of hesperidin in people 55 to 75, run by Min Hou. It plans to enroll about 105 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 55 to 75. Conditions: Cognitive Dysfunction; Overweight and Obesity.
Age 55-75 years
BMI ≥ 24 kg/m² or waist circumference ≥ 90 cm (men) / ≥ 85 cm (women)
Willing to participate and sign informed consent
The exclusion criteria are on the listing.
What it tests, as registered
Hesperidin
Registered summary
A randomized, double-blind, placebo-controlled trial was designed to test whether two doses of hesperidin (a natural flavonoid from citrus fruits) improve cognitive function in overweight and obese older adults. A total of 105 participants, aged 55-75 years with a BMI ≥24 kg/m² or elevated waist circumference, will be randomly assigned to one of three 10-week treatments: placebo, low-dose hesperidin (300 mg/day), or high-dose hesperidin (600 mg/day). The full summary is on the listing.
Where, as registered
No US site; China (1).
RecruitingNCT07452562
Hesperidin RCT in MS
No phase
Swansea University
About 60 people
Started Jan 7, 2026
In plain words A study of hesperidin in people 18 and older, run by Swansea University. It plans to enroll about 60 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Multiple Sclerosis.
Diagnosis of Multiple Sclerosis, Aged 18 years or older.
The exclusion criteria are on the listing.
What it tests, as registered
Hesperidin; Placebo
Registered summary
This study is a randomised, double-blind, placebo-controlled trial investigating the effects of Hesperidin supplementation on cognitive function, fatigue, and stress. Participants will be randomly assigned to receive either 500mg of Hesperidin or a matching placebo daily for 12 weeks. The primary outcome is fatigue, with secondary outcomes including cognitive performance and mood. The trial seeks to determine if this dietary intervention offers symptom-alleviating benefits.